We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Glaxo-Smith-Kline’s human immunodeficiency virus (HIV) specialist company ViiV Healthcare has renewed its public-private research partnership with University of North Carolina at Chapel Hill (UNC-Chapel Hill) for another five years with a $20m investment.